ArticleThe Journal of clinical investigation2023

SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production.

Liyun Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.